title: New-onset atrial fibrillation after surgical aortic valve replacement and transcatheter aortic valve implantation: a concise review.
abstract: Surgical aortic valve replacement (SAVR) and, more recently, transcatheter aortic valve implantation (TAVI) have been shown to be the only treatments that can improve the natural cause of severe aortic valve stenosis. However, after SAVR and TAVI, the incidence of new-onset atrial fibrillation (NOAF) is 31%-64% and 4%-32%, respectively. NOAF is independently associated with adverse events such as stroke, death, and increased length of hospital stay. Increasing the knowledge of predisposing factors, optimal postprocedural monitoring, and prophylactic antiarrhythmic and antithrombotic therapy may reduce the risk of complications secondary to NOAF.
authors.affiliation: Copenhagen University Hospital, Department of Cardiology, Blegdamsvej 9, 2100 Copenhagen, Denmark. Troels.hoejsgaard@gmail.com.
authors.forename: Troels Højsgaard
authors.initials: TH
authors.lastname: Jørgensen
authors.forename: Julie Bjerre
authors.initials: JB
authors.lastname: Thygesen
authors.forename: Hans Gustav
authors.initials: HG
authors.lastname: Thyregod
authors.forename: Jesper Hastrup
authors.initials: JH
authors.lastname: Svendsen
authors.forename: Lars
authors.initials: L
authors.lastname: Søndergaard
mesh_terms: D001024:Aortic Valve Stenosis / Q000601:surgery*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D015984:Causality; D018890:Chemoprevention / Q000379:methods*; D006801:Humans; D015994:Incidence; D011183:Postoperative Complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011379:Prognosis; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D065467:Transcatheter Aortic Valve Replacement / Q000009:adverse effects* / Q000379:methods